FDA clears oral Wegovy
The FDA has approved an oral form of Wegovy after the Phase III OASIS 4 trial showed positive results — that matters because a pill is much easier for many people than weekly injections. (The company said it was preparing a U.S. launch in early January 2026.) (appliedclinicaltrialsonline.com)
Wegovy used to mean a weekly shot. Now it also means a 25 milligram tablet you take once a day, after the Food and Drug Administration approved an oral version for chronic weight management in adults with obesity or with overweight plus at least one weight-related condition. (fda.gov) The drug inside the pill is semaglutide, which copies a gut hormone called glucagon-like peptide-1 that helps people feel fuller and eat less. Novo Nordisk already sells semaglutide as the diabetes pill Rybelsus and as the injectable weight-loss drug Wegovy. (wegovy.com) Getting semaglutide into a pill is unusually hard because stomach acid and digestive enzymes usually break peptide drugs apart before they can be absorbed. Novo Nordisk’s tablet uses an absorption helper called sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, which briefly helps semaglutide cross the stomach lining. (wegovy.com) The tradeoff is that the pill has to be taken more carefully than the shot. The label says adults should swallow it on an empty stomach with no more than 4 ounces of plain water and then wait at least 30 minutes before eating, drinking, or taking other oral medicines. (fda.gov) The approval rests on a late-stage study called OASIS 4, which tested 25 milligrams of oral semaglutide once daily for 64 weeks in 307 adults with obesity or overweight and at least one related medical problem, without diabetes. Participants also got lifestyle counseling. (nejm.org) People on the pill lost an average of 13.6 percent of their body weight by week 64, versus 2.2 percent on placebo. In the same trial, 79.2 percent of people on oral semaglutide lost at least 5 percent of body weight, compared with 31.7 percent on placebo. (nejm.org) Side effects looked like the rest of the glucagon-like peptide-1 drug class. The most common problems were stomach-related, including nausea, vomiting, diarrhea, constipation, abdominal pain, and indigestion, and the label carries the same boxed warning about thyroid C-cell tumors seen in rodents. (fda.gov) The dosing ramp is slower than the headline number suggests. The approved tablet starts at 1.5 milligrams daily and steps up every four weeks through 4.5, 7, and 14 milligrams before reaching the maintenance dose of 25 milligrams in week 17. (novomedlink.com) This gives Novo Nordisk two versions of the same weight-loss medicine aimed at the same disease. The injection still goes to 2.4 milligrams once weekly, while the tablet offers a needle-free option for people who are willing to follow a stricter morning routine. (novomedlink.com) The Food and Drug Administration approval letter shows Novo Nordisk filed the tablet application on January 5, 2026, and the product website is already live with pill-specific dosing and safety information. That suggests the launch work moved fast once the agency signed off. (fda.gov)
